Opyl partners with L39 Capital to launch an AI Biotech Fund leveraging TrialKey

Opyl has partnered with L39 Capital Pty Ltd to launch an AI Biotech Fund in September 2024. This collaboration aims to leverage our cutting-edge TrialKey AI technology to refine biotech investment strategies, potentially transforming the landscape of biotech and pharmaceutical stock selection.

The Partnership: A Blend of Expertise
L39 Capital Pty Ltd (L39) focuses on small-cap companies, with a team of four partners boasting diverse investment experience. By partnering with Opyl, L39 aims to harness the power of AI to drive significant capital appreciation for investors. Opyl will provide its proprietary TrialKey technology under a perpetual license, offering a competitive edge in selecting promising biotech and pharmaceutical stocks.

Why Invest in Biotech?
The biotech sector is one of the fastest-growing industries worldwide, driven by advances in genetic research, personalised medicine, and therapeutic innovations. Global biotech investments reached approximately USD $23 billion across 613 deals in 2023. However, the industry faces high failure rates in clinical trials and immense drug development costs, with less than 12% of candidate drugs in Phase 1 gaining FDA approval. These challenges highlight the substantial risk for biotech investors.

The AI Biotech Fund: Reducing Risks, Enhancing Returns
Launching in September 2024, the AI Biotech Fund aims to mitigate investment risks and enhance returns by leveraging TrialKey’s advanced AI technology. Key details include:

• • Fund Establishment and Management
    L39 will manage all aspects of the fund, including nominating an AFSL provider, custodian, and administrator, and has sourced seed funding of at least $500,000.

• • Opyl’s Compensation
    Opyl will receive an upfront payment of $25,000 and a 19.9% equity stake in the AI Fund Manager, along with a 25% share of fees earned by the fund.

• • Performance Targets
    The fund aims to grow to $100 million in assets under management (AUM) within 36 months, focusing initially on the US and Australia. TrialKey has identified at least 200 inflection points across these markets.

• • Development of TrialKey
    The AI Fund Manager will enhance TrialKey’s utility in capital raising, with Opyl providing continuous technical support and board representation.

Benefits to Opyl and Its Shareholders
This partnership is designed to create value for all stakeholders. Key benefits for Opyl and its shareholders include:

• • Revenue Generation
    The performance fees and equity stake will provide Opyl with recurring income, boosting financial stability and growth potential.

• • Market Validation
    Successful application of TrialKey in the fund will serve as proof of concept, validating its capabilities and attracting further interest from the biotech and pharmaceutical sectors.

• • Enhanced Capabilities
    Ongoing development of TrialKey will reinforce its position as the gold standard in AI-driven clinical trial design and prediction.

• • Strategic Growth
    Partnering with L39 grants Opyl access to significant expertise in fund management and biotech/pharmaceutical trading, accelerating strategic growth initiatives.

• • Improved Investor Confidence
    Targeting $100 million in AUM within 36 months will demonstrate the stability and market applicability of TrialKey, enhancing investor confidence in our technology.

The partnership between Opyl and L39 to launch an AI-driven biotech fund marks a significant milestone in biotech investment and innovation. Combining our advanced AI technology with L39’s investment expertise, this collaboration aims to revolutionise biotech stock selection, offering promising opportunities for investors and driving significant advancements in the biotech and pharmaceutical industries.